SCYNEXIS, Inc. (NASDAQ:SCYX) received a $14.00 target price from equities research analysts at HC Wainwright in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the stock.

A number of other equities research analysts also recently commented on SCYX. Roth Capital set a $9.00 price target on shares of SCYNEXIS and gave the stock a “buy” rating in a report on Monday, August 7th. Zacks Investment Research downgraded shares of SCYNEXIS from a “buy” rating to a “hold” rating in a report on Thursday, June 8th. ValuEngine upgraded shares of SCYNEXIS from a “strong sell” rating to a “sell” rating in a report on Friday, July 14th. Aegis reiterated a “buy” rating on shares of SCYNEXIS in a report on Tuesday, May 30th. Finally, Needham & Company LLC downgraded shares of SCYNEXIS from a “buy” rating to a “hold” rating in a report on Tuesday, May 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.22.

SCYNEXIS (NASDAQ:SCYX) opened at 1.66 on Wednesday. The firm has a 50-day moving average of $1.76 and a 200 day moving average of $2.32. The firm’s market capitalization is $42.82 million. SCYNEXIS has a 12-month low of $1.52 and a 12-month high of $5.51.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/16/scynexis-inc-scyx-given-a-14-00-price-target-by-hc-wainwright-analysts.html.

In related news, Director David C. Hastings bought 20,000 shares of the stock in a transaction that occurred on Wednesday, June 21st. The stock was purchased at an average cost of $1.75 per share, for a total transaction of $35,000.00. Following the completion of the acquisition, the director now owns 20,000 shares in the company, valued at $35,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.91% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in SCYX. Bank of New York Mellon Corp increased its stake in SCYNEXIS by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 37,523 shares of the company’s stock worth $103,000 after buying an additional 512 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in SCYNEXIS during the first quarter worth about $111,000. Dynamic Technology Lab Private Ltd bought a new stake in SCYNEXIS during the first quarter worth about $154,000. GSA Capital Partners LLP increased its stake in SCYNEXIS by 33.7% in the second quarter. GSA Capital Partners LLP now owns 176,700 shares of the company’s stock worth $316,000 after buying an additional 44,500 shares during the last quarter. Finally, Granite Point Capital Management L.P. bought a new stake in SCYNEXIS during the second quarter worth about $380,000. Hedge funds and other institutional investors own 48.53% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Analyst Recommendations for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.